Corvus Pharmaceuticals, Inc. (CRVS) Income Statement
CRVS 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsCRVS revenue and net income
CRVS growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
CRVS quarterly EPS vs estimates
Corvus Pharmaceuticals beat the analyst EPS estimate in 3 of the last 8 quarters. Next report: November 3, 2026 (estimate $-0.21).
CRVS income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $105,000 | $85,000 | $151,000 | $367,000 | $460,000 | $632,000 | $743,000 | $847,000 | $842,000 | $594,000 |
| Gross profit | −$105,000 | −$85,000 | −$151,000 | −$367,000 | −$460,000 | −$632,000 | −$743,000 | −$847,000 | −$842,000 | −$594,000 |
| Research & development | $33.7M | $19.4M | $16.5M | $24.5M | $29.1M | $31.8M | $38.0M | $38.6M | $46.3M | $29.4M |
| Sales, general & admin | $9.3M | $8.2M | $7.0M | $8.7M | $9.8M | $11.9M | $10.9M | $10.6M | $10.2M | $7.6M |
| Total operating expenses | $42.9M | $27.5M | $23.4M | $32.6M | $38.6M | $43.8M | $48.9M | $49.2M | $56.5M | $37.0M |
| Operating income | −$43.0M | −$27.5M | −$23.4M | −$32.6M | −$38.6M | −$43.8M | −$48.9M | −$49.2M | −$56.5M | −$37.0M |
| Interest income | $2.5M | $1.8M | $1.6M | $654,000 | $6,000 | $540,000 | $2.2M | $2.3M | $861,000 | $601,000 |
| Interest expense | $2.5M | $1.8M | $1.6M | $654,000 | $15,000 | $540,000 | $2.2M | $2.3M | $0 | $601,000 |
| Income before taxes | −$15.3M | −$62.3M | −$27.0M | −$41.3M | −$43.2M | −$6.0M | −$46.7M | −$46.9M | −$55.7M | −$36.4M |
| Income taxes | — | — | — | $8.7M | −$5.0M | −$1.2M | −$2.9M | $2.3M | −$842,000 | −$594,000 |
| Net income | −$15.3M | −$62.3M | −$27.0M | −$41.3M | −$43.2M | −$4.8M | −$43.7M | −$46.9M | −$55.7M | −$36.4M |
| EBITDA | −$15.2M | −$62.2M | −$26.9M | −$40.9M | −$42.8M | −$43.1M | −$48.1M | −$48.4M | −$55.7M | −$36.4M |
| EPS (diluted) | −$0.51 | −$0.93 | −$0.57 | −$0.89 | −$1.06 | −$1.46 | −$1.59 | −$1.75 | −$2.72 | −$6.88 |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $88,000 | $0 | $0 | $0 | $246,000 | $0 |
| Cost of revenue | — | $29,000 | $26,000 | — | $29,000 | $22,000 | $44,000 | $20,000 | $21,000 | $23,000 | $28,000 | $30,000 |
| Gross profit | — | −$29,000 | −$26,000 | — | −$29,000 | −$22,000 | $44,000 | −$20,000 | −$21,000 | −$23,000 | $218,000 | −$30,000 |
| Research & development | $16.0M | $11.2M | $9.9M | $8.5M | $7.9M | $7.5M | $6.0M | $5.2M | $4.1M | $4.1M | $4.0M | $4.0M |
| Sales, general & admin | $3.3M | $3.7M | $2.3M | $2.1M | $2.4M | $2.5M | $2.1M | $2.0M | $1.8M | $2.2M | $1.7M | $1.6M |
| Total operating expenses | $19.3M | $14.9M | $12.2M | $10.6M | $10.3M | $9.9M | $8.1M | $7.3M | $5.9M | $6.3M | $5.7M | $5.6M |
| Operating income | −$19.3M | −$14.9M | −$12.2M | −$10.6M | −$10.3M | −$9.9M | −$8.1M | −$7.3M | −$5.9M | −$6.3M | −$5.7M | −$5.6M |
| Interest income | $2.0M | $1.8M | $603,000 | $738,000 | $639,000 | $525,000 | $508,000 | $566,000 | $434,000 | $316,000 | — | $425,000 |
| Interest expense | — | $1.8M | $2.5M | $738,000 | $639,000 | $525,000 | — | $566,000 | $434,000 | $316,000 | $380,000 | $425,000 |
| Income before taxes | −$17.2M | −$13.7M | −$12.3M | −$10.2M | −$8.0M | $15.2M | −$12.1M | −$40.2M | −$4.3M | −$5.7M | −$6.7M | −$6.0M |
| Income taxes | $709,000 | — | — | — | — | — | — | — | — | −$20,276 | −$95,000 | −$425,000 |
| Net income | −$18.0M | −$13.7M | −$12.3M | −$10.2M | −$8.0M | $15.2M | −$12.1M | −$40.2M | −$4.3M | −$5.7M | −$6.7M | −$6.0M |
| EBITDA | −$17.2M | −$11.9M | −$12.3M | −$10.1M | −$8.0M | $15.2M | −$12.1M | −$40.2M | −$4.2M | −$5.7M | −$6.6M | −$6.0M |
| EPS (diluted) | −$0.19 | −$0.15 | −$0.15 | −$0.12 | −$0.10 | −$0.14 | −$0.14 | −$0.60 | −$0.07 | −$0.12 | −$0.14 | −$0.12 |
| Gross margin | — | — | — | — | — | — | 50.0% | — | — | — | 88.6% | — |
| Operating margin | — | — | — | — | — | — | −9,210.2% | — | — | — | −2,297.2% | — |
| Net margin | — | — | — | — | — | — | −13,764.8% | — | — | — | −2,704.5% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in CRVS's financial statements (latest annual report filed March 12, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
CRVS financial results
Corvus Pharmaceuticals reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $15.3 million. Diluted earnings per share came to −$0.51.
See the CRVS stock overview for the latest quote and news, or the CRVS chart for price history and technical indicators.
CRVS income statement FAQ
Does Corvus Pharmaceuticals have revenue?
Corvus Pharmaceuticals reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Corvus Pharmaceuticals profitable?
No. Corvus Pharmaceuticals reported a net loss of $15.3 million in fiscal 2025.
How much does Corvus Pharmaceuticals spend on research and development?
Corvus Pharmaceuticals spent $33.7 million on research and development in fiscal 2025.
What are Corvus Pharmaceuticals's earnings per share?
Corvus Pharmaceuticals earned $-0.51 per diluted share in fiscal 2025, compared with $-0.93 a year earlier.
When will Corvus Pharmaceuticals report its next earnings?
Corvus Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 3, 2026 after the market closes.
When does Corvus Pharmaceuticals's fiscal year end?
Corvus Pharmaceuticals's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 12, 2026.